The U.S. Food and Drug Administration (FDA) has approved the use of the Xarelto (rivaroxaban) Starter Pack for patients at risk of another deep vein thrombosis (DVT) and/or pulmonary embolism (PE) after an initial occurrence. The FDA approved rivaroxaban in November 2012 as an anticoagulant used for the treatment of DVT and/or PE. The starter pack simplifies the dosing during the initial 30-day treatment period, when patients are most susceptible to another DVT or PE, by allowing treatment to continue between hospital discharges and follow-up visits. Read more about previous FDA decisions regarding rivaroxaban.

Keywords: Anticoagulants, Morpholines, Pulmonary Embolism, Thiophenes, United States Food and Drug Administration, Venous Thrombosis

< Back to Listings